Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 4, 2016Terminated
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 4, 2016Terminated
Condition(s):Multiple MyelomaLast Updated:February 22, 2016Completed
Condition(s):Light Chain (AL) Amyloidosis, Stage 3BLast Updated:March 14, 2023Active, not recruiting
Condition(s):Light Chain Deposition Disease; Smoldering Multiple MyelomaLast Updated:September 13, 2023Active, not recruiting
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:July 4, 2012Completed
Condition(s):Multiple MyelomaLast Updated:June 14, 2022Recruiting
Condition(s):Multiple MyelomaLast Updated:August 9, 2023Active, not recruiting
Condition(s):Multiple Myeloma Stage ILast Updated:April 11, 2012Terminated
Condition(s):Multiple Myeloma; Vertebral FractureLast Updated:November 6, 2020Unknown status
Condition(s):High-risk Smoldering Multiple MyelomaLast Updated:January 27, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.